Tirzepatide pen is a new long-acting glucose-dependent insulinogenic polypeptide receptor (GIPR)/glucagon-like peptide 1 receptor (GLP-1R) agonist that combines glucose lowering and weight loss. GIP and GLP-1 can synergistically promote insulin secretion from pancreatic β cells, exerting a glucose concentration-dependent glucose lowering effect; secondly, the two can also improve pancreatic β cell function and insulin sensitivity; GLP-1 can delay gastric emptying and exert a comprehensive glucose lowering effect. Tirzepatide can achieve the goals of glucose lowering and weight loss by acting on the two targets of GIP and GLP-1. However, the efficacy results that may contribute to these improvements through GIPR agonists have not yet been fully determined. And a recent report using transgenic mouse models and single-cell RNA sequencing (scRNA-seq) analysis showed that GIPR may not be mainly expressed on adipocytes.
Tirzepatide pen experimental effect
SURMOUNT-1 is a study for adults with obesity, overweight and weight-related medical problems (excluding diabetes). A total of 2,539 subjects were recruited, and low-dose groups (5 mg/week), medium-dose groups (10 mg/week), high-dose groups (15 mg/week) and placebo groups were set up. The trial period was 72 weeks. The results showed that the high-dose group had an average weight loss of 20.9% in 72 weeks, the medium-dose group was 19.5%, the low-dose group was 15%, and the placebo group was 3.1%, and one-third of the subjects lost more than a quarter of their weight.
SURMOUNT-2 is a study of obese or overweight adults with diabetes, recruiting a total of 938 subjects. The results showed that the average weight loss of subjects in the 10 mg dose group was 13.4%, and the average weight loss of subjects in the 15 mg dose group was 15.7%, which was significantly better than the placebo group.
(Tirzepatide pen) Recommended dose and administration method
I. Recommended dose
1The recommended starting dose of Tirzepatide is 2.5 mg subcutaneously once a week. The 2.5 mg dose is for treatment initiation and is not intended for glycemic control.
2. After 4 weeks, increase the dose to 5 mg, injected subcutaneously once weekly.
3. If additional glycemic control is needed, increase the dose in 2.5 mg increments after at least 4 weeks on the current dose.
4. The maximum dose is 15 mg, injected subcutaneously once weekly.
5. If a dose is missed, instruct patients to use Tirzepatide as soon as possible within 4 days (96 hours) of the missed dose. If more than 4 days have passed, skip the missed dose and use the next dose on the regularly scheduled date and resume their regular weekly dosing schedule thereafter.
6. If necessary, the day of weekly dosing can be changed as long as the interval between doses is at least 3 days (72 hours).
Choosing an injection site
Your doctor can help you choose the injection site that is best for you. You can inject the drug into the abdomen or thigh, or you can have another person inject you in the back of your upper arm, changing (rotating) the injection site each week. You can inject into the same site, but be sure to choose a different injection site in that area.
